Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a llama IgG2b Fc tag at the C-terminus
The protein has a calculated MW of 36.7 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CEACAM-5, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human CEACAM-5, Llama IgG2b Fc Tag (Cat. No. CE5-H5259) is more than 85% and the molecular weight of this protein is around 80-108 kDa verified by SEC-MALS.
Immobilized Human CEACAM-5, Llama IgG2b Fc Tag (Cat. No. CE5-H5259) at 1 μg/mL (100 μL/well) can bind Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 with a linear range of 0.01-0.313 μg/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Intestinal Neoplasms; Gastrointestinal Diseases; Rectal Neoplasms; Brain Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Colonic Diseases; Brain metastases; Intestinal Diseases; Gastrointestinal Neoplasms | Details |
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Intestinal Neoplasms; Solid tumours; Cystadenocarcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NEO-201 | NEO-201 | Phase 2 Clinical | Precision Biologics Inc, National Cancer Institute | Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Liver Neoplasms; Colorectal Neoplasms | Details | |
LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Neoplasms | Details |
M-9140 | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
125-Iodine-labeled MFE-23 | Phase 1 Clinical | Cancer Research UK | Neoplasms | Details | |
anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis; Adenocarcinoma | Details | |
SGN-CEACAM5C | PF-08046050; SAR445953; SGN-CEACAM5C; SAR-445953 | Phase 1 Clinical | Seagen Inc, Sanofi | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
EBC-129 | EBC-129; EBC129 | Phase 1 Clinical | Experimental Drug Development Centre | Solid tumours | Details |
BGB-B167 | BGB-B167 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | Colonic Neoplasms | Details |
This web search service is supported by Google Inc.